Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments (Tables)

v3.20.2
Note 14 - Segments (Tables)
 6 Months Ended
Jun. 30, 2020
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
T
hree Months Ended
June 30
, 2020
  
Diagnostics
    
Therapeutics
    
Corporate
    
Total
  
Royalty revenue
   $
8,920
     $
—
     $
—
     $
8,920
  
Grant and other revenue
    
215,458
      
46,723
      
—
      
262,181
  
Total revenue
    
224,378
      
46,723
      
—
      
271,101
  
Cost of revenue
    
357
      
—
      
—
      
357
  
Research and development expenses
    
1,193,151
      
88,628
      
—
      
1,281,779
  
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
    
—
      
972
      
1,309,363
      
1,310,335
  
Depreciation and amortization
(2)
    
—
      
—
      
19,256
      
19,256
  
Loss from operations
(3)
    
(969,130
)
    
(42,877
)
    
(1,328,619
)
    
(2,340,626
)
Other income
(4)
    
—
      
—
      
15,007
      
15,007
  
Net loss
    
(969,130
)
    
(42,877
)
    
(1,313,612
)
    
(2,325,619
)
Total assets, net of depreciation and amortization:
                                
United States
   $
107,185
     $
36,483
     $
6,463,015
     $
6,606,683
  
Capital expenditures
    
—
      
—
      
1,947
      
1,947
  
T
hree Months Ended June 30, 2019
  
Diagnostics
    
Therapeutics
    
Corporate
    
Total
  
Royalty revenue
   $
5,940
     $
—
     $
—
     $
5,940
  
License revenue
    
9,953
      
—
      
—
      
9,953
  
Grant and other revenue
    
196,630
      
47,569
      
—
      
244,199
  
Total revenue
    
212,523
      
47,569
      
—
      
260,092
  
Cost of revenue
    
238
      
—
      
—
      
238
  
Research and development expenses
    
775,462
      
295,180
      
—
      
1,070,642
  
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
    
—
      
3,062
      
1,821,812
      
1,824,874
  
Depreciation and amortization
(2)
    
—
      
—
      
36,726
      
36,726
  
Loss from operations
(3)
    
(563,177
)
    
(250,673
)
    
(1,858,538
)
    
(2,672,388
)
Other expense
(4)
    
—
      
—
      
(1,590
)
    
(1,590
)
Income tax benefit
    
35
      
16
      
117
      
168
  
Net loss from continuing operations
    
(563,142
)
    
(250,657
)
    
(1,860,011
)
    
(2,673,810
)
Income from discontinued operations, net of tax
    
632
      
—
      
—
      
632
  
Net loss
    
(562,510
)
    
(250,657
)
    
(1,860,011
)
    
(2,673,178
)
Total assets, net of depreciation and amortization:
                                
United States
   $
220,334
     $
11,235
     $
7,892,312
     $
8,123,881
  
International
    
6,514
      
—
      
—
      
6,514
  
Six Months Ended June 30, 2020
  
Diagnostics
    
Therapeutics
    
Corporate
    
Total
  
Royalty revenue
   $
24,141
     $
—
     $
—
     $
24,141
  
Grant and other revenue
    
274,374
      
128,858
      
—
      
403,232
  
Total revenue
    
298,515
      
128,858
      
—
      
427,373
  
Cost of revenue
    
966
      
—
      
—
      
966
  
Research and development expenses
    
2,150,777
      
130,271
      
—
      
2,281,048
  
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
    
—
      
(550
)
    
3,121,796
      
3,121,246
  
Depreciation and amortization
(2)
    
—
      
—
      
36,099
      
36,099
  
Loss from operations
(3)
    
(1,853,228
)
    
(863
)
    
(3,157,895
)
    
(5,011,986
)
Other income
(4)
    
—
      
—
      
12,759
      
12,759
  
Net loss
    
(1,853,228
)
    
(863
)
    
(3,145,136
)
    
(4,999,227
)
Total assets, net of depreciation and amortization:
                                
United States
   $
107,185
     $
36,483
     $
6,463,015
     $
6,606,683
  
Capital expenditures
    
—
      
—
      
8,406
      
8,406
  
Six
Months Ended June 30, 2019
  
Diagnostics
    
Therapeutics
    
Corporate
    
Total
  
Royalty revenue
   $
9,090
     $
—
     $
—
     $
9,090
  
License revenue
    
9,953
      
—
      
—
      
9,953
  
Grant and other revenue
    
232,621
      
50,052
      
—
      
282,673
  
Total revenue
    
251,664
      
50,052
      
—
      
301,716
  
Cost of revenue
    
6,364
      
—
      
—
      
6,364
  
Research and development expenses
    
1,516,045
      
295,180
      
—
      
1,811,225
  
Selling, general and administrative expenses, excluding depreciation and amortization
(1)
    
—
      
14,776
      
3,501,835
      
3,516,611
  
Depreciation and amortization
(2)
    
—
      
—
      
73,505
      
73,505
  
Loss from operations
(3)
    
(1,270,745
)
    
(259,904
)
    
(3,575,340
)
    
(5,105,989
)
Other income
(4)
    
—
      
—
      
7,122
      
7,122
  
Provision for income tax
    
(177
)
    
(36
)
    
(495
)
    
(708
)
Net loss from continuing operations
    
(1,270,922
)
    
(259,940
)
    
(3,568,713
)
    
(5,099,575
)
Loss from discontinued operations, net of tax
    
(2,665
)
    
—
      
—
      
(2,665
)
Net loss
    
(1,273,587
)
    
(259,940
)
    
(3,568,713
)
    
(5,102,240
)
Total assets, net of depreciation and amortization:
                                
United States
   $
220,334
     $
11,235
     $
7,892,312
     $
8,123,881
  
International
    
6,514
      
—
      
—
      
6,514